<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01456936</url>
  </required_header>
  <id_info>
    <org_study_id>A3051123</org_study_id>
    <secondary_id>2010-022914-15</secondary_id>
    <secondary_id>EAGLES</secondary_id>
    <nct_id>NCT01456936</nct_id>
  </id_info>
  <brief_title>Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders</brief_title>
  <acronym>EAGLES</acronym>
  <official_title>A Phase 4, Randomized, Double-blind, Active And Placebo-controlled, Multicenter Study Evaluating The Neuropsychiatric Safety And Efficacy Of 12 Weeks Varenicline Tartrate 1mg Bid And Bupropion Hydrochloride 150mg Bid For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to assess varenicline and bupropion as aids to smoking
      cessation treatment in subjects with and without an established diagnosis of major
      psychiatric disorder and to characterize the neuropsychiatric safety profile (pre-specified
      adverse events (AEs) in both of these populations).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Neuropsychiatric (NPS) Adverse Events (AE) - the Primary Study Endpoint</measure>
    <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
    <description>The primary safety endpoint is the occurrence of at least one treatment emergent &quot;severe&quot; adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent &quot;moderate&quot; or &quot;severe&quot; adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated NPS AE Rate (%), by Cohort</measure>
    <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
    <description>The primary safety endpoint is the occurrence of at least one treatment emergent &quot;severe&quot; adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent &quot;moderate&quot; or &quot;severe&quot; adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Estimated NPS AE rate (%) was calculated based on least-squares means analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of the Components of the NPS AE Primary Endpoint, Non-psychiatric History Cohort</measure>
    <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
    <description>The safety endpoint is the occurrence of at least one treatment emergent &quot;severe&quot; adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent &quot;moderate&quot; or &quot;severe&quot; adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of the Components of the NPS AE Primary Endpoint, Psychiatric History Cohort</measure>
    <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
    <description>The safety endpoint is the occurrence of at least one treatment emergent &quot;severe&quot; adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent &quot;moderate&quot; or &quot;severe&quot; adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of the Components of NPS AE Primary Endpoint (Overall)</measure>
    <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
    <description>The NPS AE composite results (as previously described) are for the two cohorts combined and are presented below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Severe-only NPS AEs in the Primary Endpoint, by Cohort</measure>
    <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
    <description>The primary safety endpoint is the occurrence of at least one treatment emergent &quot;severe&quot; adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent &quot;moderate&quot; or &quot;severe&quot; adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Non-psychiatric History Cohort</measure>
    <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
    <description>The safety endpoint is the occurrence of at least one treatment emergent &quot;severe&quot; adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent &quot;moderate&quot; or &quot;severe&quot; adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Psychiatric History Cohort</measure>
    <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
    <description>The safety endpoint is the occurrence of at least one treatment emergent &quot;severe&quot; adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent &quot;moderate&quot; or &quot;severe&quot; adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of the Components of Severe-only NPS AE Endpoint (Overall)</measure>
    <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
    <description>The NPS AE endpoint was the occurrence of at least 1 treatment-emergent &quot;severe&quot; AE of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least 1 treatment-emergent &quot;severe&quot; AE of agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS) Total Score, Non-psychiatric History Cohort</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS Total Score, Psychiatric History Cohort</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS Total Score (Overall)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C‑SSRS) - Non-psychiatric History Cohort</measure>
    <time_frame>Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
    <description>The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent&quot;. Answers at screening are for lifetime history. Answers for all other visits are since last visit.The scale is also used to record any completed suicides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C‑SSRS) - Psychiatric History Cohort</measure>
    <time_frame>Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
    <description>The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent&quot;. Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C‑SSRS) - Overall</measure>
    <time_frame>Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
    <description>The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent&quot;. Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement (CGI‑I), &quot;No Change&quot; Rating by Visit</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The CGI-I is a clinician rated instrument that measures change in participant's psychiatric condition (or lack thereof in the stratum without psychiatric disorders) on a 7 point scale ranging from 1 (very much improved) to 7 (very much worse), with 4 = no change. The ratings were applicable even to those without psychiatric diagnoses (eg, those with no psychiatric symptoms would be rated as &quot;normal, not at all ill&quot; on the CGI-S at baseline and assuming no psychiatric symptoms emerge during the trial, would be rated as &quot;no change&quot; on the CGI-I at follow-up visits). For those participants with a psychiatric diagnosis, the clinician should rate the severity of the mental illness with respect to the clinician's experience with the psychiatric population to which the participant belongs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CO‑Confirmed Continuous Abstinence for Weeks 9 Through 12, Non-psychiatric History Cohort</measure>
    <time_frame>Week 9 through Week 12</time_frame>
    <description>A responder to this endpoint requires the answer &quot;no&quot; to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CO‑Confirmed Continuous Abstinence for Weeks 9 Through 12, Psychiatric History Cohort</measure>
    <time_frame>Week 9 through Week 12</time_frame>
    <description>A responder to this endpoint requires the answer &quot;no&quot; to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CO‑Confirmed Continuous Abstinence for Weeks 9 Through 12 (Overall)</measure>
    <time_frame>Week 9 through Week 12</time_frame>
    <description>A responder to this endpoint requires the answer &quot;no&quot; to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Non-psychiatric History Cohort</measure>
    <time_frame>Week 9 through Week 24</time_frame>
    <description>A responder to this endpoint requires the answer &quot;no&quot; to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Psychiatric History Cohort</measure>
    <time_frame>Week 9 through Week 24</time_frame>
    <description>A responder to this endpoint requires the answer &quot;no&quot; to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CO-confirmed Continuous Abstinence From Week 9 Through Week 24 (Overall)</measure>
    <time_frame>Week 9 through Week 24</time_frame>
    <description>A responder to this endpoint requires the answer &quot;no&quot; to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7‑Day Point Prevalence of Abstinence, Non-psychiatric History Cohort</measure>
    <time_frame>24 Weeks</time_frame>
    <description>A responder to this endpoint requires the answer &quot;no&quot; to both questions 3 and 6 on the nicotine use inventory at that specific visit.
NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7‑Day Point Prevalence of Abstinence, Psychiatric History Cohort</measure>
    <time_frame>24 Weeks</time_frame>
    <description>A responder to this endpoint requires the answer &quot;no&quot; to both questions 3 and 6 on the nicotine use inventory at that specific visit.
NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7‑Day Point Prevalence of Abstinence (Overall)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>A responder to this endpoint requires the answer &quot;no&quot; to both questions 3 and 6 on the nicotine use inventory at that specific visit.
NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">8144</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to placebo will receive placebo treatments for all three study drugs. Blinded placebo will be provided for varenicline, bupropion hydrochloride and transdermal nicotine patch (NRT). In addition, subjects will receive blinded placebo treatments for the study drugs they are not randomized to receive.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>varenicline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>bupropion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine Replacement Therapy Patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Triple dummy placebo for each treatment arm</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varenicline tartrate</intervention_name>
    <description>Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks</description>
    <arm_group_label>varenicline</arm_group_label>
    <other_name>Chantix; Champix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion hydrochloride</intervention_name>
    <description>Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).</description>
    <arm_group_label>bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Replacement Therapy Patch</intervention_name>
    <description>Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.</description>
    <arm_group_label>Nicotine Replacement Therapy Patch</arm_group_label>
    <other_name>NRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female cigarette smokers, 18- 75 years, motivated to stop smoking and
             considered suitable for a smoking cessation attempt.

          -  Smoked an average of at least 10 cigarettes per day during past year and during the
             month prior to the screening visit, and exhaled carbon monoxide (CO) &gt;10 ppm at
             screening.

          -  For Neuropsychiatric cohort- subjects must have proper diagnosis as outlined in
             protocol.

        Exclusion Criteria:

          -  Subjects with a past or current diagnosis of one of the following disorders:

             a. Psychotic Disorders:

          -  Schizophreniform

          -  Delusional Disorder

          -  Psychotic Disorder NOS b. All Delirium, Dementia, and Amnestic and Other Cognitive
             Disorders c. All Substance Induced Disorders (Other than nicotine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coastal Clinical Research, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NoesisPharma Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Clinical Research of Escondido</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Valley Research Center</name>
      <address>
        <city>Imperial</city>
        <state>California</state>
        <zip>92251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Clinical Trials</name>
      <address>
        <city>La Habra</city>
        <state>California</state>
        <zip>90631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Treatment and Research Center UC San Diego Health System</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine at University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North County Clinical Research</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research Center of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Neuroscience Research Medical Group, Inc.</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver, Anschutz Medical Campus , Behavioral Health and Wellness Program</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Affiliated Research Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Psychiatric Care</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research Center of Southwest Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Research Group</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions,Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Psychiatric Associates</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Behavioral Research Center</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Neurobehavioral Health</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMR-Baber Research Inc.</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network of IN, LLC</name>
      <address>
        <city>Indianaopolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davis Clinic, Incorporated</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goldpoint Clinical Research, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Research Group</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A Professional Corporation dba The Center for Sexual Health</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Research Associates</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Services</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milford Emergency Associates, Incorporated</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rahim Shafa, MD</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota- TC</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precise Research Centers</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research, PC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>St.Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Medical Institutes LLC; Princeton Medical Institute Woodlands Professional Building</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Social Psychiatry Research Institute Clinical Trials LLC</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research, Inc.</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tooley Group</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC d/b/a PMG Research of Cary</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Internal Medicine Consultants, Inc</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern PA Medical Institute</name>
      <address>
        <city>Broomall</city>
        <state>Pennsylvania</state>
        <zip>19008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belmont Center for Comprehensive Treatment</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide, LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Side Clinical Laboratory</name>
      <address>
        <city>Lincoln</city>
        <state>Rhode Island</state>
        <zip>02865</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincoln Research</name>
      <address>
        <city>Lincoln</city>
        <state>Rhode Island</state>
        <zip>02865</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical NeuroScience Solutions, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James G. Kyser, MD</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Clinical Trials, L.P.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InSite Clinical Research</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77230-1439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Psychotherapy Center, LLC</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine and Public Health</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53711-2027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Dra. De Salvo</name>
      <address>
        <city>Ciudad Autonoma de Bs. As</city>
        <state>Buenos Aires</state>
        <zip>C1426ABP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica WM</name>
      <address>
        <city>Mataderos</city>
        <state>Buenos Aires</state>
        <zip>C1440BRR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Alfred Psychiatry Research Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Messejana Dr. Carlos Alberto Studart Gomes</name>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <zip>60846-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-074</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas da PUCRS - Uniao Brasileira de Educacao e Assistencia</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital e Maternidade Celso Pierro - Pontifícia Universidade Católica de Campinas - Campus II</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13059-740</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Jaqueline Scholz Issa e Mario Issa de cardiologia S/C Ltda</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05017-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mental Health Center &quot;Prof. Dr. Ivan Temkov-Bourgas&quot; Ltd.</name>
      <address>
        <city>Bourgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBAL Dr. Hristo Stambolski EOOD</name>
      <address>
        <city>Kazanlak</city>
        <zip>6100</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DPB Sv. Ivan Rilski</name>
      <address>
        <city>Novi Iskar</city>
        <zip>1282</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMBAL Dr. Georgi Stranski EAD,</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMBAL Sveti Georgi EAD, Klinika po psihiatriya</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBALPFZ - Ruse EOOD</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsentar za psihichno zdrave - Ruse EOOD</name>
      <address>
        <city>Ruse</city>
        <zip>7004</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meditsinski Tsentar ¿Sveti Naum¿ EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHATNP Sveti Naum SJsc.</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specializirana Bolnitsa za Aktivno Lechenie na Belodrobni Bolesti-Troyan EOOD,</name>
      <address>
        <city>Troyan</city>
        <zip>5600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Medical Research Group</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Associates</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 4N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canadian Phase Onward Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3J 2C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Felix Yaroshevsky</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4W 3C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health (CAMH)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 2S1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre of Addiction and Mental Health Pharmacy</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J 1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Research Sherbrooke Inc.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Talca, Unidad de Enfermedades Respiratorias</name>
      <address>
        <city>Talca</city>
        <state>Maule</state>
        <zip>3460001</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Respiratorio Integral (CENRESIN Ltda.)</name>
      <address>
        <city>Quillota</city>
        <state>Valparaiso, V Region</state>
        <zip>2260877</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR A/S</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR A/S</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mehiläinen Leppävaara</name>
      <address>
        <city>Espoo</city>
        <zip>02600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Savon Psykiatripalvelu Oy</name>
      <address>
        <city>Kuopio</city>
        <zip>70110</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mehiläinen Nummela</name>
      <address>
        <city>Nummela</city>
        <zip>03100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu Mentalcare</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Porin Lääkäritalo Oy</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PEL, Psykiatrian ErikoiLääkärit</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZSL - Zentrum fuer Medizinische Studien Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Berlin-Mitte GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig Maximilians-Universitaet Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Respiratorio de Mexico S.C.</name>
      <address>
        <city>Mexico</city>
        <state>D.f.</state>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultarios de Medicina Especializada del Sector Privado</name>
      <address>
        <city>Colonia Hipodromo Condesa</city>
        <state>Mexico DF</state>
        <zip>06100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Enfermedades Cronicas y de Procedimientos Especiales S.C.</name>
      <address>
        <city>Morelia</city>
        <state>Michoacan</state>
        <zip>58249</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios Clinicos y Especialidades Medicas S.C.</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64620</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Clinical Trials</name>
      <address>
        <city>Rotorua</city>
        <zip>3010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;Federal Medical Research Center of Psychiatry and Addiction Medicine&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI Moscow Scientific Research Institute of Psychiatry&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Public Healthcare Institution Mental Clinical Hospital #1 n.a. N.A. Alexeeva</name>
      <address>
        <city>Moscow</city>
        <zip>117152</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Mental Hospital #12 of Moscow Healthcare Department</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Psychiatric Hospital #1 of Nizhni Novgorod</name>
      <address>
        <city>Nizhni Novgorod</city>
        <zip>603155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;Saint-Petersburg Scientific Research Psychoneurological Institute n.a. V.M. Bekhterev&quot; of MoH</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>192019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI HPE ##Smolensk State Medical Academy## of MoH of RF</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smolensk State Medical Academy of Ministry of Healthcare of Russian Federation</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Healthcare Institution, St. Nikolay Chudotvorets Mental Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution &quot;Psychoneurological Dispensary #2</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatricka ambulancia, Mentum, s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>82007</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vavrusová consulting s.r.o., Nestatna psychiatricka ambulancia, MUDr. Livia Vavrusova, PhD</name>
      <address>
        <city>Bratislava</city>
        <zip>851 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatricka ambulancia MUDr. Nada Kuriackova, s.r.o.</name>
      <address>
        <city>Levice</city>
        <zip>93401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatricka ambulancia, PsychoLine s.r.o.</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>979 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnica s poliklinikou sv. Barbory Roznava a.s.</name>
      <address>
        <city>Roznava</city>
        <zip>04801</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flexivest Fourteen Research Center</name>
      <address>
        <city>Bellville</city>
        <state>Cape Town</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worthwhile Clinical Trials</name>
      <address>
        <city>Benoni, Johannesburg</city>
        <state>Gauteng</state>
        <zip>1500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vista Clinic</name>
      <address>
        <city>Centurion</city>
        <state>Gauteng</state>
        <zip>0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soweto Clinical Trials Centre</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1818</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I Engelbrecht Research Pty, Ltd</name>
      <address>
        <city>Lyttelton</city>
        <state>Gauteng</state>
        <zip>0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midrand Medical Centre</name>
      <address>
        <city>Midrand</city>
        <state>Gauteng</state>
        <zip>1685</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Durban</city>
        <state>Kwa-Zulu Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Randles Road Medical Centre</name>
      <address>
        <city>Durban</city>
        <state>Kwazulu Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr John OBrien Incorporated</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>8001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad Especializada en Tabaquismo de la Comunidad de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Torrero La Paz</name>
      <address>
        <city>Zaragoza</city>
        <zip>50007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2011</study_first_submitted>
  <study_first_submitted_qc>October 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2011</study_first_posted>
  <results_first_submitted>January 12, 2016</results_first_submitted>
  <results_first_submitted_qc>March 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2016</results_first_posted>
  <last_update_submitted>May 9, 2016</last_update_submitted>
  <last_update_submitted_qc>May 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smoking cessation</keyword>
  <keyword>psychiatric disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Varenicline</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 11,186 participants were screened for participation in the study, of which 3042 participants were considered to be screen failures, leaving 8144 participants eligible for study participation (efficacy population). 86 participants (1.1%) did not receive study drug. A total of 8058 participants received study drug (safety population).</recruitment_details>
      <pre_assignment_details>Participants were classified into 2 cohorts: participants without diagnosis of psychiatric disorder and participants with a stable diagnosis of psychiatric disorder confirmed by the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (SCID) 4th edition conducted at screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Varenicline</title>
          <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg daily once (QD) x 3 days, 0.5 mg twice daily (BID) x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
        </group>
        <group group_id="P2">
          <title>Bupropion</title>
          <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
        </group>
        <group group_id="P3">
          <title>NRT Patch</title>
          <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2037"/>
                <participants group_id="P2" count="2034"/>
                <participants group_id="P3" count="2038"/>
                <participants group_id="P4" count="2035"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized and Treated</title>
              <participants_list>
                <participants group_id="P1" count="2016"/>
                <participants group_id="P2" count="2006"/>
                <participants group_id="P3" count="2022"/>
                <participants group_id="P4" count="2014"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1598"/>
                <participants group_id="P2" count="1586"/>
                <participants group_id="P3" count="1557"/>
                <participants group_id="P4" count="1552"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="439"/>
                <participants group_id="P2" count="448"/>
                <participants group_id="P3" count="481"/>
                <participants group_id="P4" count="483"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer meets eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient clinical response</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer willing to participate</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="218"/>
                <participants group_id="P3" count="224"/>
                <participants group_id="P4" count="248"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="126"/>
                <participants group_id="P3" count="144"/>
                <participants group_id="P4" count="127"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medication error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event (study drug)</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event (study drug unrelated)</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis population contained all treated participants i.e. who received at least one partial dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Varenicline 1.0 mg BID</title>
          <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
        </group>
        <group group_id="B2">
          <title>Bupropion</title>
          <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
        </group>
        <group group_id="B3">
          <title>NRT Patch</title>
          <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2016"/>
            <count group_id="B2" value="2006"/>
            <count group_id="B3" value="2022"/>
            <count group_id="B4" value="2014"/>
            <count group_id="B5" value="8058"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" spread="12.4"/>
                    <measurement group_id="B2" value="46.3" spread="12.6"/>
                    <measurement group_id="B3" value="46.8" spread="12.2"/>
                    <measurement group_id="B4" value="46.4" spread="12.2"/>
                    <measurement group_id="B5" value="46.5" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1114"/>
                    <measurement group_id="B2" value="1116"/>
                    <measurement group_id="B3" value="1141"/>
                    <measurement group_id="B4" value="1138"/>
                    <measurement group_id="B5" value="4509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="902"/>
                    <measurement group_id="B2" value="890"/>
                    <measurement group_id="B3" value="881"/>
                    <measurement group_id="B4" value="876"/>
                    <measurement group_id="B5" value="3549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Neuropsychiatric (NPS) Adverse Events (AE) - the Primary Study Endpoint</title>
        <description>The primary safety endpoint is the occurrence of at least one treatment emergent “severe” adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent “moderate” or “severe” adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide.</description>
        <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
        <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Neuropsychiatric (NPS) Adverse Events (AE) - the Primary Study Endpoint</title>
          <description>The primary safety endpoint is the occurrence of at least one treatment emergent “severe” adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent “moderate” or “severe” adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide.</description>
          <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2022"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-psychiatric cohort (N= 990, 989, 1006, 999)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="2.2"/>
                    <measurement group_id="O3" value="2.5"/>
                    <measurement group_id="O4" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric cohort (N= 1026, 1017, 1016, 1015)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="6.7"/>
                    <measurement group_id="O3" value="5.2"/>
                    <measurement group_id="O4" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall (N= 2016, 2006, 2022, 2014)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="3.9"/>
                    <measurement group_id="O4" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The reduced (final) statistical model included treatment group, cohort and region, plus the 2-way interaction of treatment by cohort. Other interactions not included due to lack of significance. Region reduced to 2-level to address event sparseness issue.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0652</p_value>
            <p_value_desc>An interaction between treatment and cohort was considered significant at 10% level. No multiplicity adjustments were utilized.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>A generalized linear regression analysis based on the safety analysis set was used to evaluate incidence of NPS AE as the primary analysis.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Estimated NPS AE Rate (%), by Cohort</title>
        <description>The primary safety endpoint is the occurrence of at least one treatment emergent “severe” adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent “moderate” or “severe” adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Estimated NPS AE rate (%) was calculated based on least-squares means analysis.</description>
        <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
        <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated NPS AE Rate (%), by Cohort</title>
          <description>The primary safety endpoint is the occurrence of at least one treatment emergent “severe” adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent “moderate” or “severe” adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Estimated NPS AE rate (%) was calculated based on least-squares means analysis.</description>
          <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
          <units>percentage of participants</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2022"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-psychiatric cohort (N=3984)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="0.60" upper_limit="1.90"/>
                    <measurement group_id="O2" value="2.44" lower_limit="1.52" upper_limit="3.36"/>
                    <measurement group_id="O3" value="2.31" lower_limit="1.37" upper_limit="3.25"/>
                    <measurement group_id="O4" value="2.52" lower_limit="1.58" upper_limit="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric cohort (N= 4074)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.42" lower_limit="4.91" upper_limit="7.93"/>
                    <measurement group_id="O2" value="6.62" lower_limit="5.09" upper_limit="8.15"/>
                    <measurement group_id="O3" value="5.20" lower_limit="3.84" upper_limit="6.56"/>
                    <measurement group_id="O4" value="4.83" lower_limit="3.51" upper_limit="6.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-psychiatric cohort</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.40</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
            <estimate_desc>Risk difference for varenicline versus placebo from estimation model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-psychiatric cohort</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.37</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>Risk difference for bupropion 150 mg BID versus placebo from estimation model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-psychiatric cohort</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.54</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>Risk difference for NRT versus placebo from estimation model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Psychiatric cohort</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>3.59</ci_upper_limit>
            <estimate_desc>Risk difference for varenicline versus placebo from estimation model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Psychiatric cohort</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>3.81</ci_upper_limit>
            <estimate_desc>Risk difference for bupropion 150 mg BID versus placebo from estimation model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Psychiatric cohort</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.53</ci_lower_limit>
            <ci_upper_limit>2.26</ci_upper_limit>
            <estimate_desc>Risk difference for NRT versus placebo from estimation model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of the Components of the NPS AE Primary Endpoint, Non-psychiatric History Cohort</title>
        <description>The safety endpoint is the occurrence of at least one treatment emergent “severe” adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent “moderate” or “severe” adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below.</description>
        <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
        <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of the Components of the NPS AE Primary Endpoint, Non-psychiatric History Cohort</title>
          <description>The safety endpoint is the occurrence of at least one treatment emergent “severe” adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent “moderate” or “severe” adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below.</description>
          <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="990"/>
                <count group_id="O2" value="989"/>
                <count group_id="O3" value="1006"/>
                <count group_id="O4" value="999"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling abnormal (severe only)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hostility (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agitation (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggression (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delusions (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hallucinations (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mania (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Panic (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paranoia (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychosis (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homicidal ideation (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal behavior (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal ideation (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicide (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of the Components of the NPS AE Primary Endpoint, Psychiatric History Cohort</title>
        <description>The safety endpoint is the occurrence of at least one treatment emergent “severe” adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent “moderate” or “severe” adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below.</description>
        <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
        <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of the Components of the NPS AE Primary Endpoint, Psychiatric History Cohort</title>
          <description>The safety endpoint is the occurrence of at least one treatment emergent “severe” adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent “moderate” or “severe” adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below.</description>
          <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1026"/>
                <count group_id="O2" value="1017"/>
                <count group_id="O3" value="1016"/>
                <count group_id="O4" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling abnormal (severe only)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hostility (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agitation (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggression (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delusions (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hallucinations (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mania (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Panic (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paranoia (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychosis (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homicidal ideation (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal behavior (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal ideation (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicide (moderate and severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of the Components of NPS AE Primary Endpoint (Overall)</title>
        <description>The NPS AE composite results (as previously described) are for the two cohorts combined and are presented below.</description>
        <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
        <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of the Components of NPS AE Primary Endpoint (Overall)</title>
          <description>The NPS AE composite results (as previously described) are for the two cohorts combined and are presented below.</description>
          <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2022"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hostility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hallucination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Panic Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paranoia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homicidal Ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Severe-only NPS AEs in the Primary Endpoint, by Cohort</title>
        <description>The primary safety endpoint is the occurrence of at least one treatment emergent “severe” adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent “moderate” or “severe” adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.</description>
        <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
        <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Severe-only NPS AEs in the Primary Endpoint, by Cohort</title>
          <description>The primary safety endpoint is the occurrence of at least one treatment emergent “severe” adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent “moderate” or “severe” adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.</description>
          <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2022"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-psychiatric cohort (N= 990, 989, 1006, 999)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.3"/>
                    <measurement group_id="O4" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric cohort (N= 1026, 1017, 1016, 1015)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall (N= 2016, 2006, 2022, 2014)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="0.8"/>
                    <measurement group_id="O4" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Non-psychiatric History Cohort</title>
        <description>The safety endpoint is the occurrence of at least one treatment emergent “severe” adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent “moderate” or “severe” adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.</description>
        <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
        <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Non-psychiatric History Cohort</title>
          <description>The safety endpoint is the occurrence of at least one treatment emergent “severe” adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent “moderate” or “severe” adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.</description>
          <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="990"/>
                <count group_id="O2" value="989"/>
                <count group_id="O3" value="1006"/>
                <count group_id="O4" value="999"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hostility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hallucinations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Panic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paranoia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homicidal ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Psychiatric History Cohort</title>
        <description>The safety endpoint is the occurrence of at least one treatment emergent “severe” adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent “moderate” or “severe” adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.</description>
        <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
        <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Psychiatric History Cohort</title>
          <description>The safety endpoint is the occurrence of at least one treatment emergent “severe” adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent “moderate” or “severe” adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.</description>
          <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1026"/>
                <count group_id="O2" value="1017"/>
                <count group_id="O3" value="1016"/>
                <count group_id="O4" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hostility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hallucinations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Panic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paranoia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homicidal ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of the Components of Severe-only NPS AE Endpoint (Overall)</title>
        <description>The NPS AE endpoint was the occurrence of at least 1 treatment-emergent “severe” AE of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least 1 treatment-emergent “severe” AE of agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.</description>
        <time_frame>Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
        <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of the Components of Severe-only NPS AE Endpoint (Overall)</title>
          <description>The NPS AE endpoint was the occurrence of at least 1 treatment-emergent “severe” AE of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least 1 treatment-emergent “severe” AE of agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.</description>
          <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2022"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hostility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hallucination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Panic Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paranoia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homicidal Ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Anxiety and Depression Scale (HADS) Total Score, Non-psychiatric History Cohort</title>
        <description>The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Anxiety and Depression Scale (HADS) Total Score, Non-psychiatric History Cohort</title>
          <description>The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.</description>
          <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="990"/>
                <count group_id="O2" value="989"/>
                <count group_id="O3" value="1006"/>
                <count group_id="O4" value="999"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (N= 984, 972, 989, 992)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" spread="3.92"/>
                    <measurement group_id="O2" value="3.58" spread="4.25"/>
                    <measurement group_id="O3" value="3.06" spread="3.87"/>
                    <measurement group_id="O4" value="3.38" spread="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (N= 961, 954, 963, 970)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="3.86"/>
                    <measurement group_id="O2" value="3.07" spread="3.96"/>
                    <measurement group_id="O3" value="2.84" spread="3.85"/>
                    <measurement group_id="O4" value="3.20" spread="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (N= 935, 930, 936, 941)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" spread="3.85"/>
                    <measurement group_id="O2" value="2.64" spread="3.82"/>
                    <measurement group_id="O3" value="2.63" spread="3.93"/>
                    <measurement group_id="O4" value="2.77" spread="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N= 923, 916, 934, 923)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="3.66"/>
                    <measurement group_id="O2" value="2.36" spread="3.57"/>
                    <measurement group_id="O3" value="2.46" spread="3.80"/>
                    <measurement group_id="O4" value="2.77" spread="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (N= 911, 897, 906, 902)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="3.51"/>
                    <measurement group_id="O2" value="2.24" spread="3.52"/>
                    <measurement group_id="O3" value="2.32" spread="3.86"/>
                    <measurement group_id="O4" value="2.48" spread="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N= 899, 893, 909, 897)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="3.56"/>
                    <measurement group_id="O2" value="2.18" spread="3.57"/>
                    <measurement group_id="O3" value="2.40" spread="3.87"/>
                    <measurement group_id="O4" value="2.48" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (N= 868, 861, 877, 877)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="3.60"/>
                    <measurement group_id="O2" value="2.16" spread="3.70"/>
                    <measurement group_id="O3" value="2.28" spread="3.60"/>
                    <measurement group_id="O4" value="2.64" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (N= 853, 844, 852, 846)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="3.89"/>
                    <measurement group_id="O2" value="1.96" spread="3.24"/>
                    <measurement group_id="O3" value="2.33" spread="3.80"/>
                    <measurement group_id="O4" value="2.57" spread="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (N= 772, 768, 750, 742)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="3.48"/>
                    <measurement group_id="O2" value="1.83" spread="3.21"/>
                    <measurement group_id="O3" value="2.01" spread="3.51"/>
                    <measurement group_id="O4" value="2.46" spread="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (N= 797, 796, 789, 807)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="3.74"/>
                    <measurement group_id="O2" value="1.85" spread="3.22"/>
                    <measurement group_id="O3" value="2.01" spread="3.47"/>
                    <measurement group_id="O4" value="2.38" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (N= 784, 797, 775, 789)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="3.47"/>
                    <measurement group_id="O2" value="1.90" spread="3.43"/>
                    <measurement group_id="O3" value="2.09" spread="3.61"/>
                    <measurement group_id="O4" value="2.34" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (N= 771, 785, 762, 772)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.10" spread="3.54"/>
                    <measurement group_id="O2" value="1.93" spread="3.36"/>
                    <measurement group_id="O3" value="1.97" spread="3.53"/>
                    <measurement group_id="O4" value="2.31" spread="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (N= 758, 748, 737, 758)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" spread="3.49"/>
                    <measurement group_id="O2" value="1.87" spread="3.47"/>
                    <measurement group_id="O3" value="2.01" spread="3.45"/>
                    <measurement group_id="O4" value="2.25" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HADS Total Score, Psychiatric History Cohort</title>
        <description>The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Total Score, Psychiatric History Cohort</title>
          <description>The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.</description>
          <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1026"/>
                <count group_id="O2" value="1017"/>
                <count group_id="O3" value="1016"/>
                <count group_id="O4" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (N= 1026, 1017, 1015, 1015)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.76" spread="6.14"/>
                    <measurement group_id="O2" value="7.58" spread="6.87"/>
                    <measurement group_id="O3" value="6.82" spread="6.33"/>
                    <measurement group_id="O4" value="6.70" spread="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (N= 1005, 1004, 996, 995)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.42" spread="6.36"/>
                    <measurement group_id="O2" value="6.99" spread="6.47"/>
                    <measurement group_id="O3" value="6.64" spread="6.55"/>
                    <measurement group_id="O4" value="6.42" spread="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (N= 947, 961, 945, 926)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.99" spread="6.21"/>
                    <measurement group_id="O2" value="6.51" spread="6.39"/>
                    <measurement group_id="O3" value="6.30" spread="6.55"/>
                    <measurement group_id="O4" value="6.02" spread="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N= 935, 938, 929, 908)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.87" spread="6.39"/>
                    <measurement group_id="O2" value="6.36" spread="6.55"/>
                    <measurement group_id="O3" value="6.16" spread="6.51"/>
                    <measurement group_id="O4" value="6.04" spread="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (N= 918, 918, 914, 895)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.58" spread="6.32"/>
                    <measurement group_id="O2" value="6.03" spread="6.41"/>
                    <measurement group_id="O3" value="5.82" spread="6.44"/>
                    <measurement group_id="O4" value="5.80" spread="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N= 917, 914, 912, 874)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.39" spread="6.14"/>
                    <measurement group_id="O2" value="5.87" spread="6.41"/>
                    <measurement group_id="O3" value="5.62" spread="6.22"/>
                    <measurement group_id="O4" value="5.75" spread="6.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (N= 887, 893, 878, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.43" spread="6.24"/>
                    <measurement group_id="O2" value="5.96" spread="6.68"/>
                    <measurement group_id="O3" value="5.63" spread="6.36"/>
                    <measurement group_id="O4" value="5.63" spread="6.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (N= 864, 865, 864, 823)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.38" spread="6.35"/>
                    <measurement group_id="O2" value="5.72" spread="6.50"/>
                    <measurement group_id="O3" value="5.64" spread="6.30"/>
                    <measurement group_id="O4" value="5.55" spread="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (N= 790, 803, 798, 749)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="6.09"/>
                    <measurement group_id="O2" value="5.66" spread="6.63"/>
                    <measurement group_id="O3" value="5.44" spread="6.30"/>
                    <measurement group_id="O4" value="5.42" spread="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (N= 813, 812, 814, 763)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" spread="6.11"/>
                    <measurement group_id="O2" value="5.44" spread="6.54"/>
                    <measurement group_id="O3" value="5.36" spread="6.20"/>
                    <measurement group_id="O4" value="5.09" spread="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (N= 795, 805, 791, 748)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.26" spread="6.35"/>
                    <measurement group_id="O2" value="5.62" spread="6.68"/>
                    <measurement group_id="O3" value="5.44" spread="6.34"/>
                    <measurement group_id="O4" value="5.37" spread="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (N= 784, 784, 763, 737)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="6.02"/>
                    <measurement group_id="O2" value="5.54" spread="6.44"/>
                    <measurement group_id="O3" value="5.46" spread="6.18"/>
                    <measurement group_id="O4" value="5.26" spread="6.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (N= 770, 764, 758, 729)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.21" spread="6.27"/>
                    <measurement group_id="O2" value="5.69" spread="6.64"/>
                    <measurement group_id="O3" value="5.57" spread="6.32"/>
                    <measurement group_id="O4" value="5.04" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HADS Total Score (Overall)</title>
        <description>The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Total Score (Overall)</title>
          <description>The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.</description>
          <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2021"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (N= 1989, 1976, 1985, 1987)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.03" spread="5.45"/>
                    <measurement group_id="O2" value="5.61" spread="6.07"/>
                    <measurement group_id="O3" value="4.95" spread="5.58"/>
                    <measurement group_id="O4" value="5.05" spread="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (N= 1938, 1937, 1931, 1929)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.68" spread="5.55"/>
                    <measurement group_id="O2" value="5.06" spread="5.73"/>
                    <measurement group_id="O3" value="4.74" spread="5.70"/>
                    <measurement group_id="O4" value="4.80" spread="5.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (N= 1882, 1891, 1881, 1867)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.31" spread="5.44"/>
                    <measurement group_id="O2" value="4.60" spread="5.63"/>
                    <measurement group_id="O3" value="4.48" spread="5.71"/>
                    <measurement group_id="O4" value="4.38" spread="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N= 1858, 1854, 1863, 1831)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" spread="5.50"/>
                    <measurement group_id="O2" value="4.39" spread="5.65"/>
                    <measurement group_id="O3" value="4.31" spread="5.64"/>
                    <measurement group_id="O4" value="4.39" spread="5.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (N= 1829, 1815, 1820, 1797)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94" spread="5.37"/>
                    <measurement group_id="O2" value="4.16" spread="5.52"/>
                    <measurement group_id="O3" value="4.08" spread="5.59"/>
                    <measurement group_id="O4" value="4.14" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N= 1816, 1807, 1821, 1771)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" spread="5.27"/>
                    <measurement group_id="O2" value="4.05" spread="5.52"/>
                    <measurement group_id="O3" value="4.01" spread="5.42"/>
                    <measurement group_id="O4" value="4.09" spread="5.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (N= 1755, 1754, 1755, 1736)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" spread="5.36"/>
                    <measurement group_id="O2" value="4.10" spread="5.75"/>
                    <measurement group_id="O3" value="3.96" spread="5.43"/>
                    <measurement group_id="O4" value="4.12" spread="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (N= 1717, 1709, 1716, 1669)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.85" spread="5.49"/>
                    <measurement group_id="O2" value="3.86" spread="5.48"/>
                    <measurement group_id="O3" value="4.00" spread="5.47"/>
                    <measurement group_id="O4" value="4.04" spread="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (N= 1562, 1571, 1548, 1491)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="5.21"/>
                    <measurement group_id="O2" value="3.79" spread="5.58"/>
                    <measurement group_id="O3" value="3.78" spread="5.42"/>
                    <measurement group_id="O4" value="3.95" spread="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (N= 1610, 1608, 1603, 1570)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="5.29"/>
                    <measurement group_id="O2" value="3.66" spread="5.47"/>
                    <measurement group_id="O3" value="3.71" spread="5.32"/>
                    <measurement group_id="O4" value="3.70" spread="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (N= 1579, 1602, 1566, 1537)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="5.37"/>
                    <measurement group_id="O2" value="3.77" spread="5.63"/>
                    <measurement group_id="O3" value="3.78" spread="5.44"/>
                    <measurement group_id="O4" value="3.82" spread="5.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (N= 1555, 1569, 1525, 1509)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65" spread="5.18"/>
                    <measurement group_id="O2" value="3.73" spread="5.44"/>
                    <measurement group_id="O3" value="3.72" spread="5.33"/>
                    <measurement group_id="O4" value="3.75" spread="5.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (N= 1528, 1512, 1495, 1487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.62" spread="5.33"/>
                    <measurement group_id="O2" value="3.80" spread="5.64"/>
                    <measurement group_id="O3" value="3.82" spread="5.41"/>
                    <measurement group_id="O4" value="3.62" spread="5.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C‑SSRS) - Non-psychiatric History Cohort</title>
        <description>The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent&quot;. Answers at screening are for lifetime history. Answers for all other visits are since last visit.The scale is also used to record any completed suicides.</description>
        <time_frame>Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
        <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C‑SSRS) - Non-psychiatric History Cohort</title>
          <description>The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent&quot;. Answers at screening are for lifetime history. Answers for all other visits are since last visit.The scale is also used to record any completed suicides.</description>
          <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
          <units>participants with positive responses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="990"/>
                <count group_id="O2" value="989"/>
                <count group_id="O3" value="1006"/>
                <count group_id="O4" value="999"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Suicidal Behavior (Screening lifetime)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Ideation (Screening lifetime)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Behavior (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Ideation (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Behavior (treatment emergent 12 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Ideation (treatment emergent 12 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C‑SSRS) - Psychiatric History Cohort</title>
        <description>The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent&quot;. Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides.</description>
        <time_frame>Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
        <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C‑SSRS) - Psychiatric History Cohort</title>
          <description>The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent&quot;. Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides.</description>
          <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
          <units>participants with positive responses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1026"/>
                <count group_id="O2" value="1017"/>
                <count group_id="O3" value="1016"/>
                <count group_id="O4" value="1015"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Suicidal Behavior (Screening lifetime)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="143"/>
                    <measurement group_id="O3" value="111"/>
                    <measurement group_id="O4" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Ideation (Screening lifetime)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338"/>
                    <measurement group_id="O2" value="357"/>
                    <measurement group_id="O3" value="333"/>
                    <measurement group_id="O4" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Behavior (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Ideation (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Behavior (treatment emergent 12 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Ideation (treatment emergent 12 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C‑SSRS) - Overall</title>
        <description>The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent&quot;. Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides.</description>
        <time_frame>Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
        <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C‑SSRS) - Overall</title>
          <description>The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent&quot;. Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides.</description>
          <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
          <units>participants with positive responses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2022"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Suicidal Behavior (Screening lifetime)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="118"/>
                    <measurement group_id="O4" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Ideation (Screening lifetime)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386"/>
                    <measurement group_id="O2" value="400"/>
                    <measurement group_id="O3" value="383"/>
                    <measurement group_id="O4" value="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Behavior (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Ideation (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Behavior (treatment emergent 12 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Ideation (treatment emergent 12 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Improvement (CGI‑I), &quot;No Change&quot; Rating by Visit</title>
        <description>The CGI-I is a clinician rated instrument that measures change in participant's psychiatric condition (or lack thereof in the stratum without psychiatric disorders) on a 7 point scale ranging from 1 (very much improved) to 7 (very much worse), with 4 = no change. The ratings were applicable even to those without psychiatric diagnoses (eg, those with no psychiatric symptoms would be rated as &quot;normal, not at all ill&quot; on the CGI-S at baseline and assuming no psychiatric symptoms emerge during the trial, would be rated as &quot;no change&quot; on the CGI-I at follow-up visits). For those participants with a psychiatric diagnosis, the clinician should rate the severity of the mental illness with respect to the clinician's experience with the psychiatric population to which the participant belongs.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression of Improvement (CGI‑I), &quot;No Change&quot; Rating by Visit</title>
          <description>The CGI-I is a clinician rated instrument that measures change in participant's psychiatric condition (or lack thereof in the stratum without psychiatric disorders) on a 7 point scale ranging from 1 (very much improved) to 7 (very much worse), with 4 = no change. The ratings were applicable even to those without psychiatric diagnoses (eg, those with no psychiatric symptoms would be rated as &quot;normal, not at all ill&quot; on the CGI-S at baseline and assuming no psychiatric symptoms emerge during the trial, would be rated as &quot;no change&quot; on the CGI-I at follow-up visits). For those participants with a psychiatric diagnosis, the clinician should rate the severity of the mental illness with respect to the clinician's experience with the psychiatric population to which the participant belongs.</description>
          <population>The safety dataset included all participants who had received at least one partial dose of study medication (N=8058) and was used to analyze all safety endpoints.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2016"/>
                <count group_id="O2" value="2006"/>
                <count group_id="O3" value="2022"/>
                <count group_id="O4" value="2014"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (N= 1986, 1974, 1986, 1982)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2"/>
                    <measurement group_id="O2" value="93.2"/>
                    <measurement group_id="O3" value="94.6"/>
                    <measurement group_id="O4" value="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (N= 1934, 1936, 1927, 1926)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8"/>
                    <measurement group_id="O2" value="90.8"/>
                    <measurement group_id="O3" value="90.5"/>
                    <measurement group_id="O4" value="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (N= 1880, 1892, 1880, 1863)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.3"/>
                    <measurement group_id="O2" value="89.8"/>
                    <measurement group_id="O3" value="88.7"/>
                    <measurement group_id="O4" value="87.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N= 1860, 1856, 1858, 1834)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.6"/>
                    <measurement group_id="O2" value="88.0"/>
                    <measurement group_id="O3" value="87.1"/>
                    <measurement group_id="O4" value="86.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (N= 1828, 1816, 1822, 1802)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="86.5"/>
                    <measurement group_id="O3" value="85.5"/>
                    <measurement group_id="O4" value="85.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N= 1816, 1808, 1820, 1773)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.2"/>
                    <measurement group_id="O2" value="86.5"/>
                    <measurement group_id="O3" value="85.1"/>
                    <measurement group_id="O4" value="84.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (N= 1758, 1756, 1755, 1738)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4"/>
                    <measurement group_id="O2" value="83.6"/>
                    <measurement group_id="O3" value="82.8"/>
                    <measurement group_id="O4" value="81.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (N= 1717, 1707, 1715, 1675)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6"/>
                    <measurement group_id="O2" value="81.7"/>
                    <measurement group_id="O3" value="80.4"/>
                    <measurement group_id="O4" value="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (N= 1558, 1572, 1540, 1492)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9"/>
                    <measurement group_id="O2" value="75.1"/>
                    <measurement group_id="O3" value="72.2"/>
                    <measurement group_id="O4" value="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (N= 1612, 16081602, 1575)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.9"/>
                    <measurement group_id="O2" value="76.7"/>
                    <measurement group_id="O3" value="75.2"/>
                    <measurement group_id="O4" value="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (N= 1586, 1606, 1568, 1541)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2"/>
                    <measurement group_id="O2" value="76.7"/>
                    <measurement group_id="O3" value="73.9"/>
                    <measurement group_id="O4" value="73.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (N= 1563, 1573, 1523, 1510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="72.2"/>
                    <measurement group_id="O4" value="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (N= 1533, 1515, 1499, 1497)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8"/>
                    <measurement group_id="O2" value="72.3"/>
                    <measurement group_id="O3" value="71.1"/>
                    <measurement group_id="O4" value="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CO‑Confirmed Continuous Abstinence for Weeks 9 Through 12, Non-psychiatric History Cohort</title>
        <description>A responder to this endpoint requires the answer “no” to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).</description>
        <time_frame>Week 9 through Week 12</time_frame>
        <population>The full analysis set was defined under the intent-to-treat (ITT) principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>CO‑Confirmed Continuous Abstinence for Weeks 9 Through 12, Non-psychiatric History Cohort</title>
          <description>A responder to this endpoint requires the answer “no” to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).</description>
          <population>The full analysis set was defined under the intent-to-treat (ITT) principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1005"/>
                <count group_id="O2" value="1001"/>
                <count group_id="O3" value="1013"/>
                <count group_id="O4" value="1009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0"/>
                    <measurement group_id="O2" value="26.1"/>
                    <measurement group_id="O3" value="26.4"/>
                    <measurement group_id="O4" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment, cohort, region, treatment by cohort interaction, and region by cohort interaction. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.20</ci_lower_limit>
            <ci_upper_limit>5.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment, cohort, region, treatment by cohort interaction, and region by cohort interaction. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.80</ci_lower_limit>
            <ci_upper_limit>2.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment, cohort, region, treatment by cohort interaction, and region by cohort interaction. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.83</ci_lower_limit>
            <ci_upper_limit>2.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CO‑Confirmed Continuous Abstinence for Weeks 9 Through 12, Psychiatric History Cohort</title>
        <description>A responder to this endpoint requires the answer “no” to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).</description>
        <time_frame>Week 9 through Week 12</time_frame>
        <population>The full analysis set was defined under the ITT principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>CO‑Confirmed Continuous Abstinence for Weeks 9 Through 12, Psychiatric History Cohort</title>
          <description>A responder to this endpoint requires the answer “no” to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).</description>
          <population>The full analysis set was defined under the ITT principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1032"/>
                <count group_id="O2" value="1033"/>
                <count group_id="O3" value="1025"/>
                <count group_id="O4" value="1026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2"/>
                    <measurement group_id="O2" value="19.3"/>
                    <measurement group_id="O3" value="20.4"/>
                    <measurement group_id="O4" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment, cohort, region, treatment by cohort interaction, and region by cohort interaction. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.56</ci_lower_limit>
            <ci_upper_limit>4.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment, cohort, region, treatment by cohort interaction, and region by cohort interaction. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.46</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment, cohort, region, treatment by cohort interaction, and region by cohort interaction. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.56</ci_lower_limit>
            <ci_upper_limit>2.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CO‑Confirmed Continuous Abstinence for Weeks 9 Through 12 (Overall)</title>
        <description>A responder to this endpoint requires the answer “no” to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).</description>
        <time_frame>Week 9 through Week 12</time_frame>
        <population>The full analysis set was defined under the ITT principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>CO‑Confirmed Continuous Abstinence for Weeks 9 Through 12 (Overall)</title>
          <description>A responder to this endpoint requires the answer “no” to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).</description>
          <population>The full analysis set was defined under the ITT principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2037"/>
                <count group_id="O2" value="2034"/>
                <count group_id="O3" value="2038"/>
                <count group_id="O4" value="2035"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5"/>
                    <measurement group_id="O2" value="22.6"/>
                    <measurement group_id="O3" value="23.4"/>
                    <measurement group_id="O4" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment and region. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.07</ci_lower_limit>
            <ci_upper_limit>4.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment and region. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.75</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment and region. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.82</ci_lower_limit>
            <ci_upper_limit>2.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Non-psychiatric History Cohort</title>
        <description>A responder to this endpoint requires the answer “no” to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).</description>
        <time_frame>Week 9 through Week 24</time_frame>
        <population>The full analysis set was defined under the ITT principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Non-psychiatric History Cohort</title>
          <description>A responder to this endpoint requires the answer “no” to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).</description>
          <population>The full analysis set was defined under the ITT principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1005"/>
                <count group_id="O2" value="1001"/>
                <count group_id="O3" value="1013"/>
                <count group_id="O4" value="1009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="18.5"/>
                    <measurement group_id="O4" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment, cohort, region, treatment by cohort interaction, and region by cohort interaction. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.33</ci_lower_limit>
            <ci_upper_limit>3.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment, cohort, region, treatment by cohort interaction, and region by cohort interaction. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.54</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment, cohort, region, treatment by cohort interaction, and region by cohort interaction. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.51</ci_lower_limit>
            <ci_upper_limit>2.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Psychiatric History Cohort</title>
        <description>A responder to this endpoint requires the answer “no” to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).</description>
        <time_frame>Week 9 through Week 24</time_frame>
        <population>The full analysis set was defined under the ITT principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Psychiatric History Cohort</title>
          <description>A responder to this endpoint requires the answer “no” to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).</description>
          <population>The full analysis set was defined under the ITT principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1032"/>
                <count group_id="O2" value="1033"/>
                <count group_id="O3" value="1025"/>
                <count group_id="O4" value="1026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                    <measurement group_id="O2" value="13.7"/>
                    <measurement group_id="O3" value="13.0"/>
                    <measurement group_id="O4" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment, cohort, region, treatment by cohort interaction, and region by cohort interaction. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.90</ci_lower_limit>
            <ci_upper_limit>3.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment, cohort, region, treatment by cohort interaction, and region by cohort interaction. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.33</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment, cohort, region, treatment by cohort interaction, and region by cohort interaction. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.24</ci_lower_limit>
            <ci_upper_limit>2.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CO-confirmed Continuous Abstinence From Week 9 Through Week 24 (Overall)</title>
        <description>A responder to this endpoint requires the answer “no” to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).</description>
        <time_frame>Week 9 through Week 24</time_frame>
        <population>The full analysis set was defined under the ITT principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>CO-confirmed Continuous Abstinence From Week 9 Through Week 24 (Overall)</title>
          <description>A responder to this endpoint requires the answer “no” to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).</description>
          <population>The full analysis set was defined under the ITT principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2037"/>
                <count group_id="O2" value="2034"/>
                <count group_id="O3" value="2038"/>
                <count group_id="O4" value="2035"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                    <measurement group_id="O2" value="16.2"/>
                    <measurement group_id="O3" value="15.7"/>
                    <measurement group_id="O4" value="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment and region. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.28</ci_lower_limit>
            <ci_upper_limit>3.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment and region. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.56</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The analysis was done using a logistic regression with terms treatment and region. Region reduced to 2-level for consistency with primary safety model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.49</ci_lower_limit>
            <ci_upper_limit>2.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7‑Day Point Prevalence of Abstinence, Non-psychiatric History Cohort</title>
        <description>A responder to this endpoint requires the answer “no” to both questions 3 and 6 on the nicotine use inventory at that specific visit.
NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?</description>
        <time_frame>24 Weeks</time_frame>
        <population>The full analysis set was defined under the ITT principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>7‑Day Point Prevalence of Abstinence, Non-psychiatric History Cohort</title>
          <description>A responder to this endpoint requires the answer “no” to both questions 3 and 6 on the nicotine use inventory at that specific visit.
NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?</description>
          <population>The full analysis set was defined under the ITT principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1005"/>
                <count group_id="O2" value="1001"/>
                <count group_id="O3" value="1013"/>
                <count group_id="O4" value="1009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="1.2"/>
                    <measurement group_id="O4" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9"/>
                    <measurement group_id="O2" value="21.3"/>
                    <measurement group_id="O3" value="15.5"/>
                    <measurement group_id="O4" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0"/>
                    <measurement group_id="O2" value="26.6"/>
                    <measurement group_id="O3" value="22.1"/>
                    <measurement group_id="O4" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3"/>
                    <measurement group_id="O2" value="27.7"/>
                    <measurement group_id="O3" value="25.9"/>
                    <measurement group_id="O4" value="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4"/>
                    <measurement group_id="O2" value="29.8"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0"/>
                    <measurement group_id="O2" value="31.4"/>
                    <measurement group_id="O3" value="30.4"/>
                    <measurement group_id="O4" value="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="35.2"/>
                    <measurement group_id="O3" value="35.1"/>
                    <measurement group_id="O4" value="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3"/>
                    <measurement group_id="O2" value="31.0"/>
                    <measurement group_id="O3" value="31.4"/>
                    <measurement group_id="O4" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1"/>
                    <measurement group_id="O2" value="34.9"/>
                    <measurement group_id="O3" value="34.8"/>
                    <measurement group_id="O4" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4"/>
                    <measurement group_id="O2" value="31.0"/>
                    <measurement group_id="O3" value="31.1"/>
                    <measurement group_id="O4" value="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6"/>
                    <measurement group_id="O2" value="34.1"/>
                    <measurement group_id="O3" value="34.9"/>
                    <measurement group_id="O4" value="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="30.5"/>
                    <measurement group_id="O3" value="30.4"/>
                    <measurement group_id="O4" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1"/>
                    <measurement group_id="O2" value="30.7"/>
                    <measurement group_id="O3" value="29.9"/>
                    <measurement group_id="O4" value="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5"/>
                    <measurement group_id="O2" value="33.5"/>
                    <measurement group_id="O3" value="32.0"/>
                    <measurement group_id="O4" value="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8"/>
                    <measurement group_id="O2" value="33.2"/>
                    <measurement group_id="O3" value="32.4"/>
                    <measurement group_id="O4" value="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2"/>
                    <measurement group_id="O2" value="28.5"/>
                    <measurement group_id="O3" value="28.1"/>
                    <measurement group_id="O4" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7"/>
                    <measurement group_id="O2" value="31.9"/>
                    <measurement group_id="O3" value="31.4"/>
                    <measurement group_id="O4" value="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9"/>
                    <measurement group_id="O2" value="31.3"/>
                    <measurement group_id="O3" value="31.7"/>
                    <measurement group_id="O4" value="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.9"/>
                    <measurement group_id="O2" value="31.2"/>
                    <measurement group_id="O3" value="31.2"/>
                    <measurement group_id="O4" value="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1"/>
                    <measurement group_id="O2" value="27.5"/>
                    <measurement group_id="O3" value="26.3"/>
                    <measurement group_id="O4" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                    <measurement group_id="O2" value="30.3"/>
                    <measurement group_id="O3" value="29.3"/>
                    <measurement group_id="O4" value="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7"/>
                    <measurement group_id="O2" value="29.9"/>
                    <measurement group_id="O3" value="29.0"/>
                    <measurement group_id="O4" value="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6"/>
                    <measurement group_id="O2" value="30.6"/>
                    <measurement group_id="O3" value="28.3"/>
                    <measurement group_id="O4" value="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6"/>
                    <measurement group_id="O2" value="26.0"/>
                    <measurement group_id="O3" value="27.0"/>
                    <measurement group_id="O4" value="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7‑Day Point Prevalence of Abstinence, Psychiatric History Cohort</title>
        <description>A responder to this endpoint requires the answer “no” to both questions 3 and 6 on the nicotine use inventory at that specific visit.
NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?</description>
        <time_frame>24 Weeks</time_frame>
        <population>The full analysis set was defined under the ITT principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>7‑Day Point Prevalence of Abstinence, Psychiatric History Cohort</title>
          <description>A responder to this endpoint requires the answer “no” to both questions 3 and 6 on the nicotine use inventory at that specific visit.
NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?</description>
          <population>The full analysis set was defined under the ITT principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1032"/>
                <count group_id="O2" value="1033"/>
                <count group_id="O3" value="1025"/>
                <count group_id="O4" value="1026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8"/>
                    <measurement group_id="O2" value="14.6"/>
                    <measurement group_id="O3" value="13.0"/>
                    <measurement group_id="O4" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                    <measurement group_id="O2" value="18.1"/>
                    <measurement group_id="O3" value="17.9"/>
                    <measurement group_id="O4" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6"/>
                    <measurement group_id="O2" value="21.3"/>
                    <measurement group_id="O3" value="21.1"/>
                    <measurement group_id="O4" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5"/>
                    <measurement group_id="O2" value="21.8"/>
                    <measurement group_id="O3" value="22.4"/>
                    <measurement group_id="O4" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="22.7"/>
                    <measurement group_id="O3" value="23.3"/>
                    <measurement group_id="O4" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8"/>
                    <measurement group_id="O2" value="25.4"/>
                    <measurement group_id="O3" value="27.5"/>
                    <measurement group_id="O4" value="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7"/>
                    <measurement group_id="O2" value="22.1"/>
                    <measurement group_id="O3" value="24.6"/>
                    <measurement group_id="O4" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2"/>
                    <measurement group_id="O2" value="26.0"/>
                    <measurement group_id="O3" value="29.4"/>
                    <measurement group_id="O4" value="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1"/>
                    <measurement group_id="O2" value="24.3"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6"/>
                    <measurement group_id="O2" value="27.4"/>
                    <measurement group_id="O3" value="29.4"/>
                    <measurement group_id="O4" value="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0"/>
                    <measurement group_id="O2" value="23.9"/>
                    <measurement group_id="O3" value="24.9"/>
                    <measurement group_id="O4" value="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7"/>
                    <measurement group_id="O2" value="22.6"/>
                    <measurement group_id="O3" value="24.0"/>
                    <measurement group_id="O4" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="26.8"/>
                    <measurement group_id="O4" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4"/>
                    <measurement group_id="O2" value="25.3"/>
                    <measurement group_id="O3" value="26.0"/>
                    <measurement group_id="O4" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1"/>
                    <measurement group_id="O2" value="21.9"/>
                    <measurement group_id="O3" value="21.8"/>
                    <measurement group_id="O4" value="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                    <measurement group_id="O2" value="24.0"/>
                    <measurement group_id="O3" value="24.8"/>
                    <measurement group_id="O4" value="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7"/>
                    <measurement group_id="O2" value="24.5"/>
                    <measurement group_id="O3" value="24.7"/>
                    <measurement group_id="O4" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6"/>
                    <measurement group_id="O2" value="24.7"/>
                    <measurement group_id="O3" value="25.1"/>
                    <measurement group_id="O4" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6"/>
                    <measurement group_id="O2" value="20.4"/>
                    <measurement group_id="O3" value="25.1"/>
                    <measurement group_id="O4" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7"/>
                    <measurement group_id="O2" value="23.2"/>
                    <measurement group_id="O3" value="23.7"/>
                    <measurement group_id="O4" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1"/>
                    <measurement group_id="O2" value="22.9"/>
                    <measurement group_id="O3" value="23.6"/>
                    <measurement group_id="O4" value="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5"/>
                    <measurement group_id="O2" value="23.5"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1"/>
                    <measurement group_id="O2" value="20.4"/>
                    <measurement group_id="O3" value="20.1"/>
                    <measurement group_id="O4" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7‑Day Point Prevalence of Abstinence (Overall)</title>
        <description>A responder to this endpoint requires the answer “no” to both questions 3 and 6 on the nicotine use inventory at that specific visit.
NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?</description>
        <time_frame>24 Weeks</time_frame>
        <population>The full analysis set was defined under the ITT principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline 1.0 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O2">
            <title>Bupropion 150 mg BID</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
          </group>
          <group group_id="O3">
            <title>NRT Patch</title>
            <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
          </group>
        </group_list>
        <measure>
          <title>7‑Day Point Prevalence of Abstinence (Overall)</title>
          <description>A responder to this endpoint requires the answer “no” to both questions 3 and 6 on the nicotine use inventory at that specific visit.
NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?</description>
          <population>The full analysis set was defined under the ITT principle as all randomized participants (N=8144) and was used for all efficacy endpoints.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2037"/>
                <count group_id="O2" value="2034"/>
                <count group_id="O3" value="2038"/>
                <count group_id="O4" value="2035"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="0.9"/>
                    <measurement group_id="O4" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="14.2"/>
                    <measurement group_id="O4" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3"/>
                    <measurement group_id="O2" value="22.3"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4"/>
                    <measurement group_id="O2" value="24.4"/>
                    <measurement group_id="O3" value="23.5"/>
                    <measurement group_id="O4" value="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4"/>
                    <measurement group_id="O2" value="25.7"/>
                    <measurement group_id="O3" value="25.1"/>
                    <measurement group_id="O4" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8"/>
                    <measurement group_id="O2" value="26.9"/>
                    <measurement group_id="O3" value="26.8"/>
                    <measurement group_id="O4" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5"/>
                    <measurement group_id="O2" value="30.2"/>
                    <measurement group_id="O3" value="31.3"/>
                    <measurement group_id="O4" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4"/>
                    <measurement group_id="O2" value="26.5"/>
                    <measurement group_id="O3" value="28.0"/>
                    <measurement group_id="O4" value="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6"/>
                    <measurement group_id="O2" value="30.4"/>
                    <measurement group_id="O3" value="32.1"/>
                    <measurement group_id="O4" value="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7"/>
                    <measurement group_id="O2" value="27.6"/>
                    <measurement group_id="O3" value="28.0"/>
                    <measurement group_id="O4" value="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5"/>
                    <measurement group_id="O2" value="30.7"/>
                    <measurement group_id="O3" value="32.1"/>
                    <measurement group_id="O4" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6"/>
                    <measurement group_id="O2" value="27.1"/>
                    <measurement group_id="O3" value="27.6"/>
                    <measurement group_id="O4" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8"/>
                    <measurement group_id="O2" value="26.5"/>
                    <measurement group_id="O3" value="26.9"/>
                    <measurement group_id="O4" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5"/>
                    <measurement group_id="O2" value="29.2"/>
                    <measurement group_id="O3" value="29.4"/>
                    <measurement group_id="O4" value="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                    <measurement group_id="O2" value="29.2"/>
                    <measurement group_id="O3" value="29.2"/>
                    <measurement group_id="O4" value="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1"/>
                    <measurement group_id="O2" value="25.1"/>
                    <measurement group_id="O3" value="24.9"/>
                    <measurement group_id="O4" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4"/>
                    <measurement group_id="O2" value="27.9"/>
                    <measurement group_id="O3" value="28.1"/>
                    <measurement group_id="O4" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2"/>
                    <measurement group_id="O2" value="27.8"/>
                    <measurement group_id="O3" value="28.2"/>
                    <measurement group_id="O4" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                    <measurement group_id="O2" value="27.9"/>
                    <measurement group_id="O3" value="28.1"/>
                    <measurement group_id="O4" value="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="23.9"/>
                    <measurement group_id="O3" value="23.7"/>
                    <measurement group_id="O4" value="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9"/>
                    <measurement group_id="O2" value="26.7"/>
                    <measurement group_id="O3" value="26.5"/>
                    <measurement group_id="O4" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                    <measurement group_id="O2" value="26.4"/>
                    <measurement group_id="O3" value="26.3"/>
                    <measurement group_id="O4" value="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0"/>
                    <measurement group_id="O2" value="27.0"/>
                    <measurement group_id="O3" value="25.3"/>
                    <measurement group_id="O4" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8"/>
                    <measurement group_id="O2" value="23.2"/>
                    <measurement group_id="O3" value="23.6"/>
                    <measurement group_id="O4" value="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline throughout the study period (16 weeks). Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.</time_frame>
      <desc>AEs were reported from the time the informed consent was signed throughout the study including 30 days after the last dose of study medication. In addition to the the standard collection of volunteered and observed AEs, neuropsychiatric AEs of interest were solicited using the Neuropsychiatric Adverse Event Interview.</desc>
      <group_list>
        <group group_id="E1">
          <title>Varenicline 1.0 mg BID</title>
          <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received varenicline titrated to the full dose during the first week in the following manner: 0.5 mg QD x 3 days, 0.5 mg BID x 4 days, then 1 mg BID for 11 weeks. They also received placebo bupropion and NRT patch, dosed in the same manner as the active medication.</description>
        </group>
        <group group_id="E2">
          <title>Bupropion</title>
          <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received bupropion 150 mg QD x 3 days and taken 150 mg BID for the remainder of the treatment period (11 weeks and 4 days). They also received placebo varenicline and NRT patch, dosed in the same manner as the active medication.</description>
        </group>
        <group group_id="E3">
          <title>NRT Patch</title>
          <description>Participants were randomized to 1 of the 3 active dosing groups that took active medication of either varenicline, bupropion, NRT in this triple-dummy design. Participants in this arm received NRT started active dosing the morning of the Week 1 visit and received a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment. They also received placebo varenicline and bupropion, dosed in the same manner as active medication.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Participants received matching placebo for varenicline, bupropion, and NRT in this triple-dummy design, and followed the same titration and dosing schedule as for the active treatments noted above.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (v18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyrotoxic crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Lobular breast carcinoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Bipolar II disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Borderline personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Suicidal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholin’s cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Female sterilisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Therapy change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Vascular rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (v18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1158" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="1033" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="1003" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="884" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="511" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="199" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="137" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="156" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="126" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="135" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="115" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="245" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="186" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="233" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="199" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="201" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="251" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="92" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="137" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="120" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="245" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="195" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="139" subjects_at_risk="2014"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="2016"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="2006"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="2022"/>
                <counts group_id="E4" subjects_affected="104" subjects_at_risk="2014"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study participating sites. Investigator may not disclose previously undisclosed confidential other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>After database lock and unblinding, one additional participant in the NRT arm of psychiatric cohort was found who had a primary endpoint event (moderate suicidal ideation) which required hospitalization; this event is not included in any analyses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

